Pembrolizumab (Keytruda) plus fluoropyrimidine- and platinum-containing chemotherapy for locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction cancer approved by FDA after being found to lower the risk of metastasis or death.
ClearNetwork will be available for a plan sponsor’s list of covered generic, branded, and specialty drugs across 65,000 retail pharmacies in the Express Scripts network.
Bristol Myers Squibb’s repotrectinib (Augtyro) approved by FDA to treat locally advanced or metastatic ROS1-positive non-small cell lung cancer.
Patients with kidney failure administered chronic hemodialysis who received DefenCath showed a statistically significant lower incidence of catheter-related bloodstream infections.
Findings suggest that participants nationwide who were offered and accessed their online medical record has more than doubled in the past eight years, but racial and ethnic disparities continue.
Parties will provide processing and packaging machinery services.
Study estimates that up to 20% of the costs for clinical research is associated with the manual transfer and verification of data from the electronic medical record to a data capture system.
New initiative highlights importance of a collaborative approach that allows patients to share their insights and contribute value to studies.
Stem Cell Reports takes a look at DTC online advertising claims that these are ‘immune boosters.’
Stephanie L. Woerner, PhD, director and principal research scientist at the MIT Center for Information Systems Research, discusses the outlook for next year among biopharma firms.
Bayer said it will explore access options for patients with follicular lymphoma currently receiving Aliqopa who have experienced a favorable response to treatment.
JMA Journal report describes how businesses in this Asian-Pacific nation are employing various strategies to reduce GHG emissions.
A demand-driven methodology for data standardization across multiple streams of acquisition could improve the sharing of real-world data worldwide.
Exparel was initially approved in 2011 for single-dose infiltration into a surgical site.
The Flowflex COVID-19 Antigen Home Test is the first over-the-counter rapid antigen test for SARS-CoV-2 to gain FDA 510(k) marketing clearance by the FDA.
New E2E workflow orchestration service is expected to simplify the processes of health systems and retail pharmacies while also reducing the risk of recalled items reaching patients.
Fruquintinib (Fruzaqla) is a significant new therapy for patients who have had limited options to treat metastatic colorectal cancer.
Tirzepatide (Zepbound; Eli Lilly and Company) will hit the US market by the end of 2023 with a list price of $1,059.87.
Rexulti was found to be a well-tolerated treatment for the debilitating symptoms of agitation associated with dementia due to Alzheimer’s disease.
Ayala Pharmaceuticals’ AL102 is a gamma secretase inhibitor being studied to treat patients with desmoid tumors.
Studies with Zenith-CKD showed significant albuminuria reduction.
There are a slew of specialist and boutique companies set up to provide high quality services and to meet the changing needs of the pharma industry.
While there are still hurdles to overcome along the way, home healthcare could deliver better patient-centered cancer care, providing improved patient outcomes, enhanced quality of life, and reduced strain on resources.
With new tech acquisition, the software company also introduces a new branded AI assistant for mobile devices specifically for the life sciences sector.
Study describes how biotech startups can avoid competing with large pharma companies for financing.
R&D teams need to accelerate how they conduct their research, get to a material, and get to market.
The newly approved Alinity m high risk human papillomavirus (HPV) assay is indicated to detect HPV and for use in routine cervical cancer screening per professional medical guidelines.
Determination will affect future vaccine cost and accessibility, including in developing countries.
Phathom Pharmaceuticals announced that it anticipates vonoprazan (Voquenza) to be commercially available by December 2023.
